Traders should monitor for FDA decision by September 27, 2026; approval would position PRAX as a commercial-stage CNS biotech with first-mover advantage in precision epilepsy. The Pediatric Review Voucher could be monetized for hundreds of millions, providing non-dilutive capital. Consider positioning ahead of the PDUFA date, especially if regulatory signals remain positive.
PRAX drugs
PRAX drug pipeline →- ▲ relutrigine 8/10 Filed/PDUFA (NDA under priority review) · PDUFA date Dec 27, 2026
- ▲ ulixacaltamide 8/10 Filed/NDA under FDA review (PDUFA January 29, 2027) · PDUFA date Jan 29, 2027
- ● vormatrigine 5/10 Phase 3
- ◆ elsunersen 4/10 Phase 2/3 (registrational)
- ● PRAX-050 Fresh report · subscribers
- 4 more · All PRAX drugs, catalysts & trials →
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 31 $322.19entry
- T+1 · 8mo ago −0.90%α −1.65% · $319.28
- T+5 · 7mo ago −0.61%α −4.56% · $320.22
- T+20 · 7mo ago −0.37%α −9.79% · $321.00
- T+60 · 5mo ago +1.74%α −10.64% · $327.79
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Praxis Precision Medicines announced FDA acceptance of its NDA for relutrigine, a first-in-class therapy for SCN2A and SCN8A developmental and epileptic encephalopathies, with a PDUFA target action date of September 27, 2026. The filing is supported by strong Phase 2 data showing robust seizure reduction, and the drug has multiple expedited designations including Breakthrough Therapy and Rare Pediatric Disease Designation.
Key Facts
- FDA accepted NDA for relutrigine with priority review and PDUFA date of September 27, 2026
- Relutrigine is first potential disease-modifying therapy for SCN2A/SCN8A DEEs, which currently have no approved targeted treatments
- NDA supported by positive interim results from EMBOLD study, stopped early for efficacy
- Relutrigine has Orphan Drug, Rare Pediatric Disease, and Breakthrough Therapy Designations
- If approved, eligible for Pediatric Review Voucher, enhancing commercial value
Financial Impact
High commercial and strategic value; potential first-in-class approval in ultra-rare pediatric epilepsy with voucher eligibility
Risk Factors
- FDA may not approve relutrigine despite priority review
- Safety or manufacturing issues could delay or block approval
- Commercial uptake may be limited by ultra-rare indication size
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3264996 |
Track record
16 reports on PRAX
4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jun 29, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $317.69 Now $310.27 +2.34% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $328.13 Now $310.27 −5.44% settles Feb 11
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $332.97 Now $310.27 −6.82% settles Feb 5
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
- Nov 4, 202612d ago Press Release Neutral 1/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $288.62 Now $310.27 +7.50% settles Jan 27
- Jun 29, 202620w ago 8-K Bearish 6/10 Entry $334.79 to $282.12 Now $310.27 +7.32% ▲ +15.73% +18.55% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $247.98 to $351.81 Now $310.27 +25.12% ▲ +41.87% +37.47% vs SPY
- Jun 2, 202623w ago Press Release Neutral 1/10 Entry $278.93 to $367.85 Now $310.27 +11.24% ▲ +31.88% +29.38% vs SPY
- May 7, 202627w ago Press Release Bullish 8/10 Entry $333.28 to $305.51 Now $310.27 −6.90% ▼ −8.33% −12.17% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers